Clinical Trial Update: Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of entinostat plus imatinib mesylate in relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia; the study was termina…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Drugs mentioned

• Entinostat (entinostat)
• Imatinib mesylate (Imatinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2017-08-08